Denali Therapeutics (DNLI) Looks Fully Valued After $195 Million Voucher Sale

Simply Wall St.06-24

Denali Therapeutics (DNLI) has agreed to sell its FDA Rare Pediatric Disease Priority Review Voucher for US$195 million in cash. This is a material non-operational move that could influence liquidity ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2645698758?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-06-24 10:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645698758","market":"nz","top_or_hot":-1,"title":"Denali Therapeutics (DNLI) Looks Fully Valued After $195 Million Voucher Sale","media":"Simply Wall St.","content":"<div>\n<p>Denali Therapeutics (DNLI) has agreed to sell its FDA Rare Pediatric Disease Priority Review Voucher for US$195 million in cash. This is a material non-operational move that could influence liquidity ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dnli/denali-therapeutics/news/denali-therapeutics-dnli-looks-fully-valued-after-195-millio\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Denali Therapeutics (DNLI) Looks Fully Valued After $195 Million Voucher Sale</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDenali Therapeutics (DNLI) Looks Fully Valued After $195 Million Voucher Sale\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-24 10:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dnli/denali-therapeutics/news/denali-therapeutics-dnli-looks-fully-valued-after-195-millio><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Denali Therapeutics (DNLI) has agreed to sell its FDA Rare Pediatric Disease Priority Review Voucher for US$195 million in cash. This is a material non-operational move that could influence liquidity ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dnli/denali-therapeutics/news/denali-therapeutics-dnli-looks-fully-valued-after-195-millio\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DCF","symbol_name":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dnli/denali-therapeutics/news/denali-therapeutics-dnli-looks-fully-valued-after-195-millio","article_id":"2645698758","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dnli/denali-therapeutics/news/denali-therapeutics-dnli-looks-fully-valued-after-195-millio","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2645698758","pubTimestamp":1782268040,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Denali Therapeutics (DNLI) has agreed to sell its FDA Rare Pediatric Disease Priority Review Voucher for US$195 million in cash. This is a material non-operational move that could influence liquidity and investor focus.\nSee our latest analysis for Denali Therapeutics.\nThe US$24.77 share price has been supported by strong recent momentum, with a 1-month share price return of 32.89% and a year-to-date share price return of 52.24%. However, the 5-year total shareholder return is down 67.78%,...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK4535":"淡马锡持仓","BK4548":"巴美列捷福持仓","DNLI":"Denali Therapeutics Inc.","BK4139":"生物科技"},"translate_title":"Denali Therapeutics(DNLI)在出售1.95亿美元代金券后看起来已完全估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"DNLI":1.5},"content_text":"Denali Therapeutics (DNLI) has agreed to sell its FDA Rare Pediatric Disease Priority Review Voucher for US$195 million in cash. This is a material non-operational move that could influence liquidity and investor focus. See our latest analysis for Denali Therapeutics. The US$24.77 share price has been supported by strong recent momentum, with a 1-month share price return of 32.89% and a year-to-date share price return of 52.24%. However, the 5-year total shareholder return is down 67.78%, showing that longer-term holders have had a much tougher experience. If this kind of move has your attention, it could be a good moment to broaden your watchlist with other biotech opportunities in healthcare AI, starting with the 38 healthcare AI stocks So with Denali Therapeutics rallying hard in the short term but still sitting on a weak multi year shareholder record, is the recent cash infusion a genuine reset that leaves upside on the table, or is the market already pricing in future growth? AdvertisementPreferred Price to Book of 4.2x: Is it justified? At a last close of $24.77, Denali Therapeutics is being valued at a P/B of 4.2x, which screens as expensive relative to the broader US biotech industry but cheaper than its closer peer group. The P/B ratio compares the stock price with the accounting value of net assets on the balance sheet. For a company like Denali Therapeutics, which is still loss making and reports no meaningful revenue, investors often lean on P/B because traditional earnings-based metrics do not yet apply. Here, the P/B of 4.2x is described as expensive versus the US Biotechs industry average of 2.6x, so the market is paying a higher price for each dollar of book value than the sector overall. However, relative to a peer average P/B of 10.5x, the same 4.2x is flagged as good value, which highlights how differently investors can price similar companies within the same space when expectations for future revenue growth and eventual profitability vary. See what the numbers say about this price — find out in our valuation breakdown. Result: Price-to-book of 4.2x (ABOUT RIGHT) However, investors still need to weigh Denali Therapeutics' continued net loss of US$508.017 million and the fact that reported revenue currently stands at zero. Find out about the key risks to this Denali Therapeutics narrative. Another view on Denali Therapeutics using our DCF model While the P/B ratio suggests Denali Therapeutics is roughly in line with peer expectations, the SWS DCF model paints a different picture. At $24.77, the stock is trading above an estimated future cash flow value of $16.08, which points to an overvalued outcome on this metric. Which signal may be more relevant for your analysis? Look into how the SWS DCF model arrives at its fair value. DNLI Discounted Cash Flow as at Jun 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Denali Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 44 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps With Denali Therapeutics showing both pressure points and potential bright spots, it makes sense to review the underlying data yourself and move quickly to form your own view using the 1 key reward and 2 important warning signs Looking for more investment ideas beyond Denali Therapeutics? If Denali Therapeutics has sharpened your focus, do not stop here. Broaden your opportunity set by scanning other stocks with clear balance sheets, income profiles, and risk levels.  Target stronger foundations by reviewing companies in the solid balance sheet and fundamentals stocks screener (48 results) to see which stocks pair financial resilience with room for growth. Hunt for mispriced opportunities using the 44 high quality undervalued stocks and see which stocks combine quality fundamentals with compressed multiples. Prioritise sleep at night holdings through the 67 resilient stocks with low risk scores and compare how different stocks stack up on stability and downside risk.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2645698758","isCrawlerRequest":true}